DOI QR코드

DOI QR Code

An in silico Appraisal to Identify High Affinity Anti-Apoptotic Synthetic Tetrapeptide Inhibitors Targeting the Mammalian Caspase 3 Enzyme

  • Kelotra, Seema (M.B Khalsa College) ;
  • Jain, Meeta (School of Biochemistry, Devi Ahilya University, Takshashila Campus) ;
  • Kelotra, Ankit (School of Biochemistry, Devi Ahilya University, Takshashila Campus) ;
  • Jain, Ish (In silico Research Laboratory, Eminent Biosciences) ;
  • Bandaru, Srinivas (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Nayarisseri, Anuraj (In silico Research Laboratory, Eminent Biosciences) ;
  • Bidwai, Anil (Index medical College)
  • Published : 2015.01.06

Abstract

Apoptosis is a general phenomenon of all multicellular organisms and caspases form a group of important proteins central to suicide of cells. Pathologies like cancer, Myocardial infarction, Stroke, Sepsis, Alzheimer's, Psoriasis, Parkinson and Huntington diseases are often associated with change in caspase 3 mediated apoptosis and therefore, caspases may serve as potential inhibitory targets for drug development. In the present study, two series of synthetic acetylated tetrapeptides containing aldehyde and fluromethyl keto groups respectively at the C terminus were proposed. All these compounds were evaluated for binding affinity against caspase 3 structure. In series 1 compound Ac-DEHD-CHO demonstrated appreciable and high binding affinity (Rerank Score: -138.899) against caspase 3. While in series 2 it was Ac-WEVD-FMK which showed higher binding affinity (Rerank Score: -139.317). Further these two compounds met ADMET properties and demonstrated to be non-toxic.

Keywords

References

  1. Li SX, Chai L, Cai ZG, et al (2012). Expression of survivin and caspase 3 in oral squamous cell carcinoma and peritumoral tissue. Asian Pac J Cancer Prev, 13, 5027-31. https://doi.org/10.7314/APJCP.2012.13.10.5027
  2. Liu DD, Ye YL, Zhang J, et al (2014). Distinct pro-apoptotic properties of Zhejiang saffron against human lung cancer via a caspase-8-9-3 cascade. Asian Pac J Cancer Prev, 15, 6075. https://doi.org/10.7314/APJCP.2014.15.15.6075
  3. Miao EA, Rajan JV, Aderem A (2011). Caspase-1-induced pyroptotic cell death. Immunol Rev, 243, 206-14. https://doi.org/10.1111/j.1600-065X.2011.01044.x
  4. Nayarisseri A (2013). In silico investigations on HSP90 and its inhibition for the therapeutic prevention of breast cancer. J Pharm Res, 7, 150-6. https://doi.org/10.1016/j.jopr.2013.02.020
  5. Noy N (2010). Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr, 30, 201-17. https://doi.org/10.1146/annurev.nutr.28.061807.155509
  6. Powers JC, Asgian JL, Ekici OD, James KE (2002). Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev, 102, 4639-750. https://doi.org/10.1021/cr010182v
  7. Sankari SL, Masthan KM, Babu NA, Bhattacharjee T, Elumalai M (2012). Apoptosis in cancer - an update. Asian Pac J Cancer Prev, 13, 4873-8. https://doi.org/10.7314/APJCP.2012.13.10.4873
  8. Shi Y (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell, 9, 459-70. https://doi.org/10.1016/S1097-2765(02)00482-3
  9. Shiozaki EN, Shi Y (2004). Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci, 29, 486-94. https://doi.org/10.1016/j.tibs.2004.07.003
  10. Takai N, Kira N, Ishii T, et al (2012). Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev, 13, 399-402. https://doi.org/10.7314/APJCP.2012.13.1.399
  11. Turk B, Stoka V (2007). Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett, 581, 2761-7. https://doi.org/10.1016/j.febslet.2007.05.038
  12. Vuree S (2013). Pharmacogenomics of drug resistance in Breast Cancer Resistance Protein (BCRP) and its mutated variants. J Pharm Res, 7, 791-8.
  13. Zou X, Liu SL, Zhou JY, et al (2012). Beta-asarone induces lovo colon cancer cell apoptosis by up-regulation of caspases through a mitochondrial pathway in vitro and in vivo. Asian Pac J Cancer Prev, 13, 5291. https://doi.org/10.7314/APJCP.2012.13.10.5291
  14. Becker JW, Rotonda J, Soisson SM, et al (2004). Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis. J Med Chem, 47, 2466-74. https://doi.org/10.1021/jm0305523
  15. Belizario JE, Alves J, Garay-Malpartida M, Occhiucci JM (2008). Coupling caspase cleavage and proteasomal degradation of proteins carrying PEST motif. Curr Protein Pept Sci, 9, 210-20. https://doi.org/10.2174/138920308784534023
  16. Chai J, Shiozaki E, Srinivasula SM, et al (2001). Structural basis of caspase-7 inhibition by XIAP. Cell, 104, 769-80. https://doi.org/10.1016/S0092-8674(01)00272-0
  17. Concha NO, Abdel-Meguid SS (2002). Controlling apoptosis by inhibition of caspases. Curr Med Chem, 9, 713-26. https://doi.org/10.2174/0929867023370761
  18. Danial NN, Korsmeyer SJ (2004). Cell death: critical control points. Cell, 116, 205-19. https://doi.org/10.1016/S0092-8674(04)00046-7
  19. An FF, Liu YC, Zhang WW, Liang, L (2013). Dihydroartemisinine enhances dictamnine-induced apoptosis via a caspase dependent pathway in human lung adenocarcinoma A549 cells. Asian Pac J Cancer Prev, 14, 5895-900. https://doi.org/10.7314/APJCP.2013.14.10.5895
  20. Arockiaraj J, Gnanam AJ, Muthukrishnan D, et al (2013). An upstream initiator caspase 10 of snakehead murrel Channa striatus, containing DED, p20 and p10 subunits: Molecular cloning, gene expression and proteolytic activity. Fish Shellfish Immunol, 34, 505-13. https://doi.org/10.1016/j.fsi.2012.11.040
  21. Denault JB, Salvesen GS (2002). Caspases: keys in the ignition of cell death. Chem Rev, 102, 4489-500. https://doi.org/10.1021/cr010183n
  22. Fischer U, Schulze-Osthoff K (2005). Apoptosis-based therapies and drug targets. Cell Death Differ, 12, 942-61. https://doi.org/10.1038/sj.cdd.4401556
  23. Gomez-Vicente V, Donovan M, Cotter TG (2005). Multiple death pathways in retina-derived 661W cells following growth factor deprivation: crosstalk between caspases and calpains. Cell Death Differ, 12, 796-804. https://doi.org/10.1038/sj.cdd.4401621
  24. Grawert MA, Groll M (2012). Exploiting nature's rich source of proteasome inhibitors as starting points in drug development. Chem Commun (Camb), 48, 1364-78. https://doi.org/10.1039/C1CC15273D
  25. Hardy B, Douglas N, Helma C, et al (2010). Collaborative development of predictive toxicology applications. J Cheminform, 2, 1-29. https://doi.org/10.1186/1758-2946-2-1
  26. Hengartner MO (2000). The biochemistry of apoptosis. Nature, 407, 770-6. https://doi.org/10.1038/35037710
  27. Huang Y, Park YC, Rich RL, et al (2001). Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell, 104, 781-90.
  28. Kuhn D, Orlowski R, Bjorklund C (2011). Second generation proteasome inhibitors: carfilzomib and immunoproteasomespecific inhibitors (IPSIs). Curr Cancer Drug Targets, 11, 285-95. https://doi.org/10.2174/156800911794519725
  29. Lavrik IN, Golks A, Krammer PH (2005). Caspases: pharmacological manipulation of cell death. J Clin Invest, 115, 2665-72. https://doi.org/10.1172/JCI26252
  30. Le GT, Abbenante G, Madala PK, Hoang HN, Fairlie DP (2006). Organic azide inhibitors of cysteine proteases. J Am Chem Soc, 128, 12396-7. https://doi.org/10.1021/ja0637649
  31. Leist M, Jaattela M (2001). Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol, 2, 589-98.